← 返回

肿瘤 MHC I 类分子表达改变由宿主 NK 细胞驱动的癌症相关髓系细胞生成

英文原题:Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells.

查看英文原题

Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells.

PubMed 2022/10/01(内容时间) J Immunother Cancer Q1 · IF 11.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤细胞上MHC I类(MHCI)分子的下调被认为是癌症免疫治疗的一种耐药机制。鉴于MHCI分子是免疫应答的有效调节因子,我们推测肿瘤细胞对MHCI的表达影响全身免疫应答。相应地,携带MHCI缺陷肿瘤细胞的小鼠脾脏中肿瘤相关髓外髓系生成减少。自然杀伤(NK)细胞的清除消除了这些差异,提示免疫调节性NK细胞在肿瘤进展过程中发挥不可或缺的作用。细胞因子谱分析显示,在携带表达MHCI肿瘤的小鼠中,肿瘤和脾脏内NK细胞的TNF-α表达上调,而抑制TNF-α增强了接受肿瘤经历NK细胞过继转移小鼠的宿主髓系生成。我们的研究强调了NK细胞超越其作为杀伤性淋巴细胞身份的关键作用,更重要的是,宿主对局部肿瘤的潜在应答由其MHCI表达所决定。

展开英文摘要原文

Downregulation of MHC class I (MHCI) molecules on tumor cells is recognized as a resistance mechanism of cancer immunotherapy. Given that MHCI molecules are potent regulators of immune responses, we postulated that the expression of MHCI by tumor cells influences systemic immune responses. Accordingly, mice-bearing MHCI-deficient tumor cells showed reduced tumor-associated extramedullary myelopoiesis in the spleen.

Depletion of natural killer (NK) cells abrogated these differences, suggesting an integral role of immune-regulatory NK cells during tumor progression. Cytokine-profiling revealed an upregulation of TNF-α by NK cells in tumors and spleen in mice-bearing MHCI expressing tumors, and inhibition of TNF-α enhanced host myelopoiesis in mice receiving adoptive transfer of tumor-experienced NK cells.

Our study highlights a critical role of NK cells beyond its identity as a killer lymphocyte and more importantly, the potential host responses to a localized tumor as determined by its MHCI expression.

论文信息

作者
Neo SY、Jing X、Tong L、Tong D、Gao J、Chen Z、De Los Santos MC、Burduli N
第一作者单位
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.Sweden
通讯作者单位
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden Andreas.Lundqvist@ki.se.Sweden
文献类型
非美国政府资助研究
期刊
Journal for immunotherapy of cancer2022 Oct
原文标识
PubMed 36283735 · DOI 10.1136/jitc-2022-005308